Kringle Pharma Company Description

Kringle Pharma, Inc. engages in the research and development, manufactures, and sells hepatocyte growth factor (HGF) protein pharmaceuticals for regenerative medicines.

The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury.

Kringle Pharma, Inc. was incorporated in 2001 and is based in Ibaraki, Japan.

Kringle Pharma, Inc.

Country	Japan
Founded	2001
Industry	Biotechnology
Sector	Healthcare
Employees	15
CEO	Kiichi Adachi

Contact Details

Address: 207 Saito Bio Incubator Ibaraki, 567-0085 Japan
Phone	81 7 2641 8739
Website	kringle-pharma.com

Stock Details

Ticker Symbol	4884
Exchange	Tokyo Stock Exchange
Stock Type	Common Stock
Fiscal Year	October - September
Reporting Currency	JPY
ISIN Number	JP3270790003
SIC Code	2836

Key Executives

Name	Position
Kiichi Adachi	Chief Executive Officer